Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bone markers and current laboratory assays.

Rosemary A Hannon1, Richard Eastell

  • 1Academic Unit of Bone Metabolism, Division of Clinical Sciences (North), University of Sheffield Clinical Sciences Centre, Northern General Hospital, Herries Rd, Sheffield S5 7AU, UK. r.a.hannon@sheffield.ac.uk

Cancer Treatment Reviews
|May 9, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An index of net bone formation relative to resorption is associated with incident fracture during the menopause transition and postmenopause.

JBMR plus·2026
Same author

Efficacy, pharmacodynamics, pharmacokinetics, safety, and immunogenicity of Bmab 1000 vs reference denosumab: 78-wk results from a randomized, double-blind, multicenter, parallel-arm Phase 3 trial (DEVOTE) in women with postmenopausal osteoporosis.

JBMR plus·2026
Same author

Natural history of thyroid function in ageing: an individual participant data analysis of 137 488 participants from 31 prospective cohort studies.

The lancet. Diabetes & endocrinology·2026
Same author

Improvement of Bone Mineral Density in Patients with Type 1 Gaucher Disease Treated with Velaglucerase Alfa: Results from Clinical Studies.

Journal of clinical medicine·2026
Same author

Monte Carlo Resampling Validates Use of Bone Mineral Density Change as Surrogate to Replace Fracture in Future Randomized Trials of Osteoporosis Treatments: Results From SABER.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026
Same author

Growth differentiation factor 15 and the risk of hip fracture in older adults.

JBMR plus·2026

Cancer metastasis to bone alters bone remodeling. Bone turnover markers, reflecting osteoclastic and osteoblastic activity, show potential for diagnosing and managing metastatic bone disease (MBD).

Area of Science:

  • Oncology
  • Orthopedics
  • Biochemistry

Background:

  • Bone metastases significantly disrupt normal bone remodeling processes.
  • Bone turnover markers (BTMs) reflect osteoclastic (resorption) and osteoblastic (formation) activity.
  • Increasing interest exists in utilizing BTMs for managing metastatic bone disease (MBD).

Purpose of the Study:

  • To review the biology of bone metastases.
  • To describe bone turnover markers.
  • To explore the role of BTMs in aiding clinicians in MBD patient treatment.

Main Methods:

  • Literature review of studies on bone metastases and bone turnover markers.
  • Discussion of the biological mechanisms of bone metastasis.
  • Analysis of the clinical applications of BTMs in MBD.

Related Experiment Videos

Main Results:

  • Bone metastases cause measurable changes in bone turnover markers.
  • BTMs offer potential for diagnosis, monitoring disease progression, and treatment efficacy assessment in MBD.
  • Studies indicate BTMs may aid in predicting patient outcomes.

Conclusions:

  • Bone turnover markers are valuable indicators of altered bone remodeling in MBD.
  • Further research and clinical application of BTMs can enhance MBD management.
  • BTMs can support clinical decision-making for patients with bone metastases.